Peptide Reclassification 2026: Which Peptides Are Legal Now?
The regulatory landscape for therapeutic peptides has shifted dramatically since 2023. Three peptides — CJC-1295, Ipamorelin, and Selank — are now legally compoundable by 503A pharmacies with a valid physician prescription. Fourteen additional peptides, including BPC-157, TB-500, and AOD-9604, have been announced for reclassification but await formal FDA publication. This article explains what has changed, what is currently legal, and how WellSpry is prescribing peptides through the most compliant model available.
The September 2023 Category 2 Restriction
In September 2023, the FDA placed dozens of therapeutic peptides on its Category 2 bulk substance list. This classification effectively prohibited 503A compounding pharmacies from producing patient-specific preparations of these compounds. The restriction was broad and swept up peptides with decades of clinical research — including BPC-157, which had been widely prescribed for gut health and tissue repair, and CJC-1295/Ipamorelin, a growth hormone secretagogue stack used by physicians for lean mass preservation and sleep quality.
Practically, Category 2 meant that even with a valid physician prescription, a 503A pharmacy could not legally compound the peptide. Patients and prescribers were left with two options: pharmaceutical-grade alternatives (which largely did not exist for these compounds) or unregulated research chemical vendors operating in a legal grey area. Neither option served patients well.
The September 2024 Partial Reversal
In September 2024, the FDA reversed its position on five peptides, moving them back to Category 1 — meaning they could once again be legally compounded by 503A pharmacies under physician prescription. The five peptides returned to legal compounding status were CJC-1295, Ipamorelin, Selank, and two others with narrower clinical applications. This was the first meaningful rollback of the 2023 restrictions.
For prescribers like WellSpry, this was significant. CJC-1295 and Ipamorelin form the backbone of the growth hormone secretagogue stack — the most commonly prescribed peptide combination for patients experiencing lean mass loss during GLP-1 therapy. Selank filled a separate but important niche: an anxiolytic heptapeptide that modulates cortisol without benzodiazepine-class side effects, directly relevant for patients whose stress hormones are blocking fat loss.
The February 2026 Kennedy Announcement
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 additional peptides would be reclassified from Category 2 to Category 1. The announcement specifically named BPC-157, TB-500 (Thymosin Beta-4), AOD-9604, KPV, MOTS-C, Semax, Emideltide (DSIP), Epitalon, GHK-Cu Injectable, Kisspeptin-10, and Thymosin Alpha-1 among the peptides returning to legal compounding status.
As of April 15, 2026, the formal FDA Federal Register publication has not been issued. This distinction matters: until the official publication appears in the Federal Register, these peptides remain technically on the Category 2 restricted list. The announcement signals intent, but the legal framework has not yet changed. WellSpry is monitoring the Federal Register daily and will begin prescribing these peptides immediately upon formal publication.
What Is Currently Legal (April 2026)
Three peptides are definitively legal for 503A compounding with a physician prescription as of April 2026:
Eleven additional peptides are expected to return to legal status upon formal FDA publication, which is anticipated in Q2–Q3 2026. The most clinically significant for WellSpry patients are BPC-157 (gut repair and tissue healing), TB-500 (muscle and tendon recovery), and AOD-9604 (fat metabolism without growth effects).
Category 1 vs. FDA Approval: An Important Distinction
Category 1 reclassification is not FDA approval. These peptides are not being approved as new drugs — they are being returned to a classification that allows licensed compounding pharmacies to prepare them under physician prescription. This is the same pathway used for bioidentical hormones, custom-dose medications, and other compounded therapeutics. The physician bears clinical responsibility for the prescription. The pharmacy bears responsibility for preparation quality. The patient receives a patient-specific compound, not a mass-produced pharmaceutical product.
The 503A Prescription Model
A 503A compounding pharmacy prepares medications for individual patients based on a specific physician prescription. This is distinct from a 503B outsourcing facility, which produces larger batches for clinical use. The 503A model provides the most personalised and physician-supervised pathway for peptide therapy. Each preparation is patient-specific, compounded to the prescribed dose and concentration, and dispensed directly to the patient.
This model requires something most peptide providers cannot offer: clinical documentation that justifies the prescription. A questionnaire asking “do you want peptides?” does not create a defensible prescription. A 100+ biomarker blood panel showing specific hormonal, inflammatory, or metabolic deficiencies does.
Why Biomarker Testing Is the Most Compliant Pathway
The fundamental question regulators and pharmacies ask about any off-label prescription is: what is the clinical justification? WellSpry's model answers this definitively. Before any peptide is prescribed, the patient has completed a 100+ biomarker blood panel, gut microbiome sequencing, and a physician interpretation call. The biomarker data creates the clinical documentation. The physician makes the prescribing decision based on objective results — not patient self-reporting.
This is what separates WellSpry from the majority of peptide clinics: the prescription is driven by data, documented in a clinical summary, and defensible under regulatory scrutiny. The physician is not prescribing because the patient wants a peptide. The physician is prescribing because the biomarkers show it is warranted.
What WellSpry Is Doing Right Now
WellSpry is currently prescribing CJC-1295, Ipamorelin, and Selank through our physician network via CareValidate, with compounds prepared by our 503A pharmacy partner Belmar Pharma Solutions. These prescriptions are introduced at the 90-day physician check-in when body composition and biomarker data justify them — not at initial intake.
Upon formal FDA publication of the remaining 11 peptides, WellSpry will expand prescribing to include BPC-157, TB-500, AOD-9604, and other compounds as warranted by individual patient biomarkers. The clinical infrastructure — testing, physician network, pharmacy relationship, and documentation workflow — is already in place. The only constraint is the regulatory timeline.
This article reflects the regulatory status of peptide compounds as of April 15, 2026. The FDA Federal Register publication for the 14 additional peptides announced by HHS Secretary Kennedy on February 27, 2026 has not been issued as of this date. WellSpry will update this article when the official publication occurs. This content is for informational purposes and does not constitute medical advice. Consult your physician before starting any peptide therapy.
Frequently Asked Questions
Which peptides are legal to prescribe in 2026?
CJC-1295, Ipamorelin, and Selank are currently legal for 503A compounding with a physician prescription. Fourteen additional peptides including BPC-157, TB-500, and AOD-9604 have been announced for reclassification but await formal FDA publication.
Is BPC-157 legal in 2026?
As of April 2026, BPC-157 remains technically on the FDA Category 2 restricted list. HHS Secretary Kennedy announced its reclassification on February 27, 2026, but formal FDA Federal Register publication has not been issued. WellSpry will begin prescribing immediately upon formal publication.
Do I need a prescription for peptides?
Yes. Even with Category 1 status, peptides require a valid physician prescription for 503A compounding. They are not available over the counter. Purchasing from unregulated research chemical vendors remains legally and medically risky.
What is a 503A compounding pharmacy?
A 503A pharmacy prepares patient-specific medications under a physician prescription. Unlike 503B outsourcing facilities that produce large batches, 503A pharmacies compound individually for each patient — the most personalised and supervised pathway for peptide therapy.
How does WellSpry prescribe peptides?
WellSpry runs a 100+ biomarker blood panel and gut microbiome test before any prescription. The biomarker data creates the clinical documentation that justifies each prescription — making WellSpry's model more compliant than questionnaire-only peptide clinics.